MICA: The exploitation of a novel image-based risk stratification tool in early prostate cancer - the Re-IMAGINE Consortium
MICA:在早期前列腺癌中开发基于图像的新型风险分层工具 - Re-IMAGINE 联盟
基本信息
- 批准号:MR/R014043/1
- 负责人:
- 金额:$ 659.92万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2018
- 资助国家:英国
- 起止时间:2018 至 无数据
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Background: One in eight men will develop prostate cancer and the risk increases with age. Most will not die of it, but some do. Our ability to identify those men whose cancer will decrease either their quality or quantity of life remains poor. Nowhere else in modern medicine are the errors of over-diagnosis, over-treatment, missed-diagnoses and poor risk-stratification more extreme. These four errors - which impact directly on the 1million men who undergo prostate biopsy each year in Europe alone - result in the application of treatments that have little or no benefit, leave men suffering with significant life-long harms and waste valuable healthcare resources. Aims:Our Re-IMAGINE Consortium has been created to undertake discovery that will correct these four key errors. We will, for the first time, be able to combine the underlying molecular changes in the cancer with state-of-the-art imaging. This will allow us to predict prostate cancer status for the individual (low, medium or high risk) without recourse to biopsy. It will also allow us to predict which prostate cancers are likely to progress over time and which are not - something that has largely eluded us so far. By doing so, men will be subject to fewer but better biopsies, improved risk stratification, appropriate treatment allocation, more benefit, less harm and more cost-effective care. Methods:We will achieve this by building on established partnerships between patients, advocacy organisations, clinicians, imaging experts, molecular biologists, methodologists and a broad range of industrial partners. The vision of Re-IMAGINE is built on our recently published work showing that magnetic resonance imaging (MRI) of the prostate was 100% better at identifying men at risk compared to the standard prostate biopsy, and moreover missed no men with potentially fatal disease. MRI is now certain to become the future cornerstone of the risk-stratification process for men at risk of early prostate cancer. However, we know very little about the use of MRI in combination with other markers in the body.Through working with patients and advocacy groups, we have developed several work strands (WS) that will allow us to realise our aims:WS1 will create the first group (cohort) of men who receive a prostate cancer diagnosis by means of an MRI-based pathway. These men will, after appropriate consent, donate some tissue, blood and urine for marker analysis. They will be recruited from 3 major centres in London that have high quality MRI in place. WS2 will test the performance of MRI in a population where cancer is less common - in men who have not had a PSA test. This will allow us to predict the exact proportion of men at risk within the community. These work streams will generate a lot of data (clinical information, imaging data, as well as information from markers in blood, tissue, and urine). We will combine all this data for each patient using a secure data warehouse and analyse it using advanced mathematical techniques. Such a complex project will require high levels of project management and coordination. This will be achieved by building on existing and fruitful collaborations. Due to its ambition, likely impact and potential for positive disruption we are pleased that the early development work was both informed and driven by patients and their families and in some specific instances (WS2) by the public. This patient and public involvement will intensify during the period of data gathering, analysis and dissemination. Impact: Re-IMAGINE will transform the management of early prostate cancer from an era in which imprecision and uncertainty was the norm to one in which any patient can expect - and benefit from - a precise prediction of his own risk and better care as a result.
背景:八分之一的男性会患上前列腺癌,并且风险随着年龄的增长而增加。大多数人不会因此而死,但有些人会。我们识别那些癌症会降低生活质量或数量的男性的能力仍然很差。在现代医学中,过度诊断、过度治疗、漏诊和风险分层不佳的错误没有比这更极端的了。这四个错误-仅在欧洲每年就直接影响到100万接受前列腺活检的男性-导致应用几乎没有或没有益处的治疗,使男性遭受重大的终身伤害,浪费宝贵的医疗资源。目标:我们的Re-IMAGINE联盟已经建立,以进行发现,将纠正这四个关键错误。我们将首次能够将癌症中潜在的分子变化与最先进的成像技术联合收割机结合起来。这将使我们能够预测个体的前列腺癌状态(低,中或高风险),而无需求助于活检。它还将使我们能够预测哪些前列腺癌可能会随着时间的推移而进展,哪些不会-这是迄今为止我们在很大程度上无法做到的。通过这样做,男性将接受更少但更好的活检,改善风险分层,适当的治疗分配,更多的好处,更少的伤害和更具成本效益的护理。方法:我们将通过建立患者、倡导组织、临床医生、成像专家、分子生物学家、方法学家和广泛的工业合作伙伴之间的合作伙伴关系来实现这一目标。Re-IMAGINE的愿景建立在我们最近发表的工作基础上,该工作表明,与标准前列腺活检相比,前列腺磁共振成像(MRI)在识别高危男性方面的效果好100%,而且没有遗漏患有潜在致命疾病的男性。MRI现在肯定会成为男性早期前列腺癌风险分层过程的未来基石。然而,我们对MRI与体内其他标志物的结合使用知之甚少。通过与患者和倡导团体的合作,我们开发了几个工作链(WS),这将使我们能够实现我们的目标:WS 1将创建第一组(队列)通过基于MRI的途径接受前列腺癌诊断的男性。这些人将在适当的同意后,捐献一些组织,血液和尿液进行标记物分析。他们将从伦敦的3个主要中心招募,这些中心拥有高质量的MRI。WS 2将在癌症不太常见的人群中测试MRI的性能--在没有接受过PSA测试的男性中。这将使我们能够预测社区内处于风险中的男性的确切比例。这些工作流将生成大量数据(临床信息、成像数据以及来自血液、组织和尿液中标记物的信息)。我们将使用一个安全的数据仓库将每个病人的所有这些数据联合收割机结合起来,并使用先进的数学技术进行分析。如此复杂的项目将需要高水平的项目管理和协调。这将通过加强现有的富有成效的合作来实现。由于其雄心,可能的影响和积极的破坏潜力,我们很高兴早期的开发工作是由患者及其家属以及在某些特定情况下(WS 2)由公众告知和推动的。在数据收集、分析和传播期间,这种耐心和公众的参与将得到加强。影响:Re-IMAGINE将把早期前列腺癌的管理从一个不精确和不确定性是常态的时代转变为一个任何患者都可以期望并受益于对自己风险的精确预测和更好的护理的时代。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Replica analysis of overfitting in generalized linear models
广义线性模型中过拟合的复制分析
- DOI:10.48550/arxiv.2004.06329
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Coolen A
- 通讯作者:Coolen A
"Something Good Has to Come Out of the Horror": A Qualitative Examination of Cancer Survivors' Attitudes Towards Participation in Research During the First Year of the COVID-19 Pandemic.
- DOI:10.3389/fpubh.2021.741188
- 发表时间:2021
- 期刊:
- 影响因子:5.2
- 作者:Fox L;Wylie H;Haire A;Green S;Kibaru J;Van Hemelrijck M
- 通讯作者:Van Hemelrijck M
Replica analysis of overfitting in generalized linear regression models
- DOI:10.1088/1751-8121/aba028
- 发表时间:2020-09-11
- 期刊:
- 影响因子:2.1
- 作者:Coolen, A. C. C.;Sheikh, M.;Antenucci, F.
- 通讯作者:Antenucci, F.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark Emberton其他文献
Data of a stiffness softening mechanism effect on proliferation and differentiation of a human bone marrow derived mesenchymal stem cell line towards the chondrogenic and osteogenic lineages
- DOI:
10.1016/j.dib.2018.09.068 - 发表时间:
2018-12-01 - 期刊:
- 影响因子:
- 作者:
Linxiao Wu;Adrián Magaz;Tao Wang;Chaozong Liu;Arnold Darbyshire;Marilena Loizidou;Mark Emberton;Martin Birchall;Wenhui Song - 通讯作者:
Wenhui Song
2049 MAGNETIC RESONANCE IMAGE-GUIDED PROSTATE BIOPSY VERSUS TRANSPERINEAL TEMPLATE PROSTATE BIOPSY IN THE DIAGNOSIS OF CLINICALLY SIGNIFICANT PROSTATE CANCER
- DOI:
10.1016/j.juro.2012.02.2214 - 发表时间:
2012-04-01 - 期刊:
- 影响因子:
- 作者:
Veeru Kasivisvanathan;Robert Dufour;Caroline Moore;Hashim Ahmed;Alex Freeman;Susan Charman;Clare Allen;Jan van der Meulen;Mark Emberton - 通讯作者:
Mark Emberton
MP53-03 TRANSPERINEAL MRI VISUALLY-TARGETED PROSTATE BIOPSIES COMPARED TO TEMPLATE MAPPING BIOPSY IN 534 MEN REQUIRING FURTHER RISK STRATIFICATION
- DOI:
10.1016/j.juro.2016.02.500 - 发表时间:
2016-04-01 - 期刊:
- 影响因子:
- 作者:
Alistair Grey;Tom Hartingon;Clare Allen;Manit Arya;Mark Emberton;Alex Freeman;Caroline Moore;Shonit Punwani;Navin Ramachandran;Giorgia Trevisan;Miles Walkden;Hashim Ahmed - 通讯作者:
Hashim Ahmed
MP67-19 MORPHOLOGICAL ASSESSMENT OF ANTERIOR LESIONS ON PROSTATE MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING.
- DOI:
10.1016/j.juro.2014.02.2086 - 发表时间:
2014-04-01 - 期刊:
- 影响因子:
- 作者:
Ahmed El-Shater Bosaily;Alex Freeman;Mark Emberton;Hashim Ahmed;Alex Kirkham - 通讯作者:
Alex Kirkham
PROSTATE CANCER RISK STRATIFICATION AND CANCER MAPPING – TEMPLATE TRANSPERINEAL PROSTATE MAPPING BIOPSIES
- DOI:
10.1016/s0022-5347(08)60444-9 - 发表时间:
2008-04-01 - 期刊:
- 影响因子:
- 作者:
Hashim U Ahmed;Daniel Stevens;Omar Barbouti;Evangelos Zacharakis;Rowland O Illing;Douglas Pendse;Clare Allen;Alex Freeman;Mark Emberton - 通讯作者:
Mark Emberton
Mark Emberton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark Emberton', 18)}}的其他基金
Centre for Image Guided Therapy - A Theranostic Approach to Patients with Cancer
图像引导治疗中心 - 癌症患者的治疗诊断方法
- 批准号:
MR/M009092/1 - 财政年份:2015
- 资助金额:
$ 659.92万 - 项目类别:
Research Grant
相似海外基金
Commercial exploitation of novel biofertilisers for increased soil health
新型生物肥料的商业开发以改善土壤健康
- 批准号:
10054609 - 财政年份:2023
- 资助金额:
$ 659.92万 - 项目类别:
Grant for R&D
Risk Screening & Primary Prevention of Elder Abuse in People Living with Dementia
风险筛查
- 批准号:
10512584 - 财政年份:2022
- 资助金额:
$ 659.92万 - 项目类别:
Identifying Risk and Improving Care for Elder Abuse among Veterans
识别退伍军人中虐待老年人的风险并改善护理
- 批准号:
10620201 - 财政年份:2022
- 资助金额:
$ 659.92万 - 项目类别:
Risk Screening & Primary Prevention of Elder Abuse in People Living with Dementia
风险筛查
- 批准号:
10703407 - 财政年份:2022
- 资助金额:
$ 659.92万 - 项目类别:
Identifying Risk and Improving Care for Elder Abuse among Veterans
识别退伍军人中虐待老年人的风险并改善护理
- 批准号:
10417675 - 财政年份:2022
- 资助金额:
$ 659.92万 - 项目类别:
Exploitation of the natural biodiversity of AAV to identify “super transducers"
利用 AAV 的自然生物多样性来识别“超级传感器”
- 批准号:
10270094 - 财政年份:2021
- 资助金额:
$ 659.92万 - 项目类别:
Social Reward Processing Across the Lifespan: Identifying Risk Factors for Financial Exploitation
整个生命周期的社会奖励处理:识别金融剥削的风险因素
- 批准号:
10213369 - 财政年份:2021
- 资助金额:
$ 659.92万 - 项目类别:
Exploitation of the natural biodiversity of AAV to identify “super transducers"
利用 AAV 的自然生物多样性来识别“超级传感器”
- 批准号:
10463809 - 财政年份:2021
- 资助金额:
$ 659.92万 - 项目类别:
RUI: Studying B-bodies, a novel type of nuclear domains: from organization to practical exploitation.
RUI:研究 B 体,一种新型核域:从组织到实际利用。
- 批准号:
2042814 - 财政年份:2021
- 资助金额:
$ 659.92万 - 项目类别:
Standard Grant
Exploitation of the natural biodiversity of AAV to identify “super transducers"
利用 AAV 的自然生物多样性来识别“超级传感器”
- 批准号:
10674952 - 财政年份:2021
- 资助金额:
$ 659.92万 - 项目类别: